US Patent

US7790755 — Controlled release preparation

Formulation · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2026-08-02 · 0y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a controlled release preparation that slowly releases an active ingredient in the gastrointestinal tract for an extended period of time.

USPTO Abstract

A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

Drugs covered by this patent

Patent Metadata

Patent number
US7790755
Jurisdiction
US
Classification
Formulation
Expires
2026-08-02
Drug substance claim
No
Drug product claim
Yes
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.